Education
About Us
Working with TipRanks
Follow Us
Sagimet Biosciences, Inc. Class A (SGMT)
NASDAQ:SGMT
SGMT Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.39 - $7.38
Previous CloseN/A
Volume1.06M
Average Volume (3M)472.08K
Market Cap
$123.62M
Enterprise Value-$63.33M
Total Cash (Recent Filing)$74.94M
Total Debt (Recent Filing)$176.00K
Price to Earnings (P/E)―
Beta3.26
Next Earnings
May 14, 2025EPS Estimate
-0.68Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.44
Shares Outstanding30,674,854
10 Day Avg. Volume306,715
30 Day Avg. Volume472,077
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)64.23
Price to Cash Flow (P/CF)-2.90
P/FCF Ratio0.00
Enterprise Value/Market Cap-0.51
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda1.85
Forecast
1Y Price Target
$32.50Price Target Upside706.45% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
---
Sagimet Biosciences, Inc. Class A News
See All SGMT News
---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe FASCINATE-3 Ph3 program for denifanstat in F2/F3 MASH patients has started, indicating progress in clinical trials.
Financial PositionSGMT has a cash reserve of $158.7M, expected to provide operational expense runway through 2025.
Market OpportunityThe opportunity in acne is seen as upside to the valuation, with a large potential market of ~50M U.S. individuals affected and a paucity of new agents in development.
Bears Say
Financial PerformanceSGMT reported a 4Q24 net loss of $16.2M, which could be a concern for financial stability.
Research And Development CostsSGMT's 4Q24 research and development expenses increased by 12% quarter over quarter, which may impact profitability.
---
Ownership Overview
10.58% Insiders
6.79% Mutual Funds
30.65% Other Institutional Investors
48.08% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SGMT FAQ
What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?
Sagimet Biosciences, Inc. Class A lowest stock price was $2.39 and its highest was $7.38 in the past 12 months.
What is Sagimet Biosciences, Inc. Class A’s market cap?
Sagimet Biosciences, Inc. Class A’s market cap is $123.62M.
When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?
Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is May 14, 2025 which is in 48 days.
How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?
Sagimet Biosciences, Inc. Class A released its earnings results on Mar 12, 2025. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.621 by $0.121.
Is Sagimet Biosciences, Inc. Class A overvalued?
According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued.
Does Sagimet Biosciences, Inc. Class A pay dividends?
Sagimet Biosciences, Inc. Class A does not currently pay dividends.
What is Sagimet Biosciences, Inc. Class A’s EPS estimate?
Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.68.
How many shares outstanding does Sagimet Biosciences, Inc. Class A have?
Sagimet Biosciences, Inc. Class A has 30,674,854 shares outstanding.
What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?
Sagimet Biosciences, Inc. Class A reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.621. Following the earnings report the stock price went up 3.235%.
Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?
Currently, no hedge funds are holding shares in SGMT
---
Sagimet Biosciences, Inc. Class A Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$32.50 (706.45% Upside)
$32.50 (706.45% Upside)
Blogger Sentiment
Bullish
SGMT Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 428.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.6%
Last 30 Days ▼ 9.6%
Last 30 Days ▼ 9.6%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.79%
12-Months-Change
Fundamentals
Return on Equity
-36.92%
Trailing 12-Months
Asset Growth
65.70%
Trailing 12-Months
Company Description
Sagimet Biosciences, Inc. Class A
Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
---
SGMT Stock 12 Month Forecast
Average Price Target
$32.50
▲(706.45% Upside)
Technical Analysis
Madrigal Pharmaceuticals
―
Viking Therapeutics
―
Akero Therapeutics
―
89bio
―
Repare Therapeutics
―
Best Analysts Covering SGMT
1 Year
1 Year Success Rate
3/6 ratings generated profit
1 Year Average Return
+10.13%
reiterated a buy rating 16 days ago
Copying Ed Arce's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +10.13% per trade.
---